Goldman Sachs’s ARS Pharmaceuticals SPRY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $25.6M | Buy |
1,464,312
+746,359
| +104% | +$13M | ﹤0.01% | 1605 |
|
|
2025
Q1 | $9.03M | Sell |
717,953
-168,164
| -19% | -$2.12M | ﹤0.01% | 2300 |
|
|
2024
Q4 | $9.35M | Buy |
886,117
+610,262
| +221% | +$6.44M | ﹤0.01% | 2385 |
|
|
2024
Q3 | $4M | Sell |
275,855
-164,884
| -37% | -$2.39M | ﹤0.01% | 2910 |
|
|
2024
Q2 | $3.75M | Sell |
440,739
-21,977
| -5% | -$187K | ﹤0.01% | 2816 |
|
|
2024
Q1 | $4.73M | Buy |
462,716
+321,615
| +228% | +$3.29M | ﹤0.01% | 2609 |
|
|
2023
Q4 | $773K | Sell |
141,101
-98,347
| -41% | -$539K | ﹤0.01% | 3741 |
|
|
2023
Q3 | $905K | Buy |
239,448
+116,295
| +94% | +$440K | ﹤0.01% | 3591 |
|
|
2023
Q2 | $825K | Sell |
123,153
-73,351
| -37% | -$491K | ﹤0.01% | 3730 |
|
|
2023
Q1 | $1.28M | Buy |
196,504
+83,609
| +74% | +$544K | ﹤0.01% | 3506 |
|
|
2022
Q4 | $963K | Buy |
112,895
+13,243
| +13% | +$113K | ﹤0.01% | 3719 |
|
|
2022
Q3 | $526K | Sell |
99,652
-23,634
| -19% | -$125K | ﹤0.01% | 4209 |
|
|
2022
Q2 | $523K | Buy |
123,286
+21,595
| +21% | +$91.6K | ﹤0.01% | 4352 |
|
|
2022
Q1 | $357K | Buy |
101,691
+23,458
| +30% | +$82.4K | ﹤0.01% | 4790 |
|
|
2021
Q4 | $521K | Buy |
78,233
+23,884
| +44% | +$159K | ﹤0.01% | 4493 |
|
|
2021
Q3 | $543K | Buy |
+54,349
| New | +$543K | ﹤0.01% | 4339 |
|
|
2021
Q1 | – | Sell |
-87,813
| Closed | -$4.07M | – | 5351 |
|
|
2020
Q4 | $4.07M | Buy |
+87,813
| New | +$4.07M | ﹤0.01% | 2587 |
|